EAN 2026 | One big question with Dr Richard Nowak: what MG advance could transform care in the next 3 years?

Richard Nowak, MD, MS, Yale School of Medicine, New Haven, CT, discusses the key advances in myasthenia gravis (MG) that could transform care in the next three years. Dr Nowak highlights the potential value of a biomarker to predict treatment response, as well as the induction of immune tolerance. This interview took place at the 12th Congress of the European Academy of Neurology (EAN) in Geneva, Switzerland.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.